Name: 글로벌 시장 동향
SKU: PH7210
Availability: InStock

보고서 요약(국문)

개요
전 세계 허혈성 뇌졸중 치료 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
허혈성 뇌졸중은 뇌의 특정 부위로 가는 혈액 공급이 차단되거나 감소하여 뇌 조직이 산소와 영양분을 공급받지 못할 때 발생합니다. 뇌세포는 몇 분 안에 죽기 시작합니다. 뇌졸중은 응급 상황이므로 즉각적인 치료가 필요합니다. 조기에 조치를 취하면 뇌 손상 및 기타 합병증을 줄일 수 있습니다.
허혈성 뇌졸중의 주요 치료법은 조직 플라스미노겐 활성제(tPA)라는 약물입니다. 이 약물은 뇌로 가는 혈류를 막는 혈전을 분해합니다. 의료진은 팔의 정맥에 tPA를 주사합니다. 이 약물은 뇌졸중 증상 발현 후 3시간 이내에 투여하면 매우 효과적입니다.

시장 동향: 성장 동력 및 제약 요인
증가하는 유병률
뇌졸중 및 뇌동맥류 발생률 증가는 향후 몇 년 동안 세계 시장 성장을 견인할 것으로 예상됩니다. 세계뇌졸중기구(World Stroke Organization)의 통계에 따르면 뇌졸중은 이미 전염병 수준에 이르렀으며, 25세 이상 성인 4명 중 1명은 평생 동안 뇌졸중을 경험할 것으로 예상됩니다. 올해 전 세계적으로 1,220만 명 이상이 첫 뇌졸중을 겪고 650만 명이 사망할 것으로 추산됩니다.
또한, 영국에서는 약 3.0%의 사람들이 뇌동맥류의 영향을 받고 있으며, 뇌동맥류 재단(Brain Aneurysm Foundation)은 매년 600만 명 이상의 미국인이 뇌동맥류로 고통받고 있다고 보고했습니다. 이 밖에도, 인식 개선 및 연구 활동 증가 등 여러 요인이 예측 기간 동안 세계 시장 성장에 기여할 것으로 예상됩니다.

대체재의 가용성
그러나 특허 만료 및 혈전 제거 장치의 출시 등은 예측 기간 동안 세계 시장 성장을 저해할 수 있는 요인으로 작용할 수 있습니다. 또한, 승인된 치료법과 전문 인력의 부족도 세계 시장 성장을 저해하는 추가적인 요인입니다.
세분화 분석
세계 허혈성 뇌졸중 치료 시장은 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
조직 플라스미노겐 활성제(tPA) 약물 종류가 시장을 주도할 것으로 예상됨
tPA는 효과적인 혈액 희석제로 뇌졸중 치료에 승인되었습니다. 이는 회복 가능성을 높여줍니다. 여러 연구에서 허혈성 뇌졸중 환자에게 tPA를 투여한 경우, 투여하지 않은 환자에 비해 완전 회복 가능성이 높거나 장애 발생 가능성이 더 낮다는 사실이 관찰되었습니다. 따라서 모든 허혈성 뇌졸중 환자에게 tPA는 1차 치료제로 사용되며, 이는 해당 부문의 성장을 촉진합니다.

또한, 2022년 1월, Thrombolytic Science, LLC는 미국 특허상표청으로부터 섬유소 용해 효소인 조직 플라스미노겐 활성제(tPA)와 유로키나제 플라스미노겐 활성제(uPA)를 이용한 허혈성 뇌졸중의 혁신적인 치료법에 대한 두 번째 특허를 획득했습니다. 이번 특허 승인은 tPA 기반 뇌졸중 치료법의 발전을 위한 발판을 마련할 것으로 기대됩니다.
지역 분석
북미, 세계 시장 주도 예상
북미 지역은 뇌졸중 및 동맥류 발병률이 증가하고 있어, 이 지역의 뇌졸중 및 동맥류 치료 시장이 세계 시장을 주도할 것으로 예상됩니다. 미국 질병통제예방센터(CDC)에 따르면, 미국에서는 매년 79만 5천 명 이상이 뇌졸중을 경험하며, 이 중 약 61만 명은 처음 뇌졸중을 겪는 환자입니다.

놀랍게도 미국에서는 약 40초마다 한 명씩 뇌졸중이 발생하고, 4분마다 한 명씩 뇌졸중으로 사망합니다. 뇌졸중은 대부분 허혈성 뇌졸중으로 전체 뇌졸중의 약 87%를 차지하며, 뇌로 가는 혈류가 차단될 때 발생합니다. 또한, 미국인 50명 중 약 1명은 파열되지 않은 뇌동맥류를 가지고 있는데, 이는 약 670만 명에 해당합니다. 연간 뇌동맥류 파열 발생률은 인구 10만 명당 8~10명으로 추산됩니다.
코로나19 영향 분석
코로나19 팬데믹으로 인해 응급 환자 치료 및 바이러스 확산 방지를 위해 의료 자원이 집중되면서, 선택적 진료 및 정기 검진이 연기되거나 중단되었습니다. 의료 인력은 과중한 업무에 시달렸고, 정규직 및 계약직 직원의 이직률이 증가하여 의료 시스템에 부담을 주고 임상 지원 제공 능력을 감소시켜 시장에 부정적인 영향을 미쳤습니다.

시장 세분화
약물 종류별
• 조직 플라스미노겐 활성제(TPA)
• 항응고제
• 항혈소판제
• 스타틴
• 항고혈압제
• 기타
투여 경로별
• 경구
• 주사
유통 채널별
• 병원 약국
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발
• 2023년 9월, Sun Pharmaceutical Industry의 완전 소유 계열사는 미국 Pharmazz Inc.와 협력하여 인도에서 뇌허혈성 뇌졸중 치료제를 상용화했습니다. • 2023년 2월, 미국 식품의약국(FDA)은 Pharmazz의 급성 뇌허혈성 뇌졸중 환자 대상 소바텔티드(PMZ-1620) 3상 임상시험 개시를 위한 임상시험계획승인서(IND)를 발급했습니다.

경쟁 환경
주요 글로벌 시장 참여 기업으로는 Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Amgen Inc., Merck and Co. Inc., Biogen Inc. 등이 있습니다.

보고서 구매 이유

• 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 허혈성 뇌졸중 치료 시장 세분화 현황을 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 허혈성 뇌졸중 치료 시장 수준의 다양한 데이터가 담긴 Excel 파일입니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 허혈성 뇌졸중 치료 시장 보고서는 약 61개의 표, 59개의 그림, 194페이지 분량입니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Ischemic Stroke Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
An ischemic stroke emerges when the blood supply to region of the brain is interrupted or decreased, stopping brain tissue from obtaining oxygen and nutrients. Brain cells start to die in minutes. A stroke is a medical crisis, and immediate attention is necessary. Premature action can lessen brain injury and additional intricacies.
The primary treatment for an ischemic stroke is a drug called tissue plasminogen activator (tPA). It busts up the blood clots that obstruct blood flow to the brain. A healthcare provider injects tPA into a vein in the arm. The drug is highly beneficial if given within 3 hours post-stroke manifestations begin.
Market Dynamics: Drivers & Restraints
Growing Prevalence
The rising events of brain stroke and aneurysms are expected to drive the growth of the global market in the coming years. As per the statistics provided by the World Stroke Organization, stroke has already reached epidemic proportions, with one out of four adults above the age of 25 expected to experience a stroke in their lifetime. It is estimated that over 12.2 million individuals worldwide will face their first stroke this year, and 6.5 million will succumb to it.
Additionally, brain aneurysm affects approximately 3.0% of people in the U.K., and the Brain Aneurysm Foundation has reported that more than 6.0 million Americans are affected by brain aneurysms every year. Furthermore, growing awareness and research activites among other factors are also expected to contribute to the global market growth during the forecast period.
Avaliability of Substituents
However, patent expiry and entry of Clot-retrieval devices are among the factors that may impede the global market growth during the forecast period. Furthermore, the lack of approved treatments available and professionals are among the additional factors hampering the global market growth.
Segment Analysis
The global ischemic stroke treatment market is segmented based on drug class, route of administration, distribution channel and region.
Tissue Plasminogen Activator Drug Class is Expected to Dominate Market
Tissue plasminogen activator is an efficacious blood thinner and is authorized for the therapy of stroke. It enhances the probability of recovery. A number of investigations observed that individuals who receive tissue plasminogen activator during their ischemic stroke have additional potential to recover totally or have more infrequent possibilities of disability than those who do not consume the medicine. Therefore, for all patients with ischemic stroke, a tissue plasminogen activator is a first-line therapy to treat, boosting the segment growth.
Moreover, in January 2022, Thrombolytic Science, LLC was awarded a second patent by the United States Patent and Trademark Office for the innovative therapy of ischemic stroke via the usage of fibrinolytic enzymes, tissue plasminogen activator, tPA, and urokinase plasminogen activator, uPA. The recent patent authorization is expected to pave the path for the evolution of tissue plasminogen activator-based treatment of stroke.
Geographical Analysis
North America is Expected to Dominate the Global Market
It is expected that the North American market will dominate the global market for stroke and aneurysm treatment due to the increasing prevalence of these conditions in the region. According to the Centers for Disease Control and Prevention, over 795,000 individuals in the United States experience a stroke each year, with approximately 610,000 of these being first or new strokes.
Shockingly, there is an estimated one stroke every 40 seconds in the United States and every four minutes, someone dies from a stroke. Stroke cases are mainly of the ischemic type, accounting for around 87% of all strokes, which occur when blood flow to the brain is blocked. Additionally, about 1 in 50 people in the United States have an unruptured brain aneurysm, which translates to approximately 6.7 million individuals. The yearly rate of rupture is estimated to be around 8-10 per 100,000 individuals.
COVID-19 Impact Analysis
Due to the COVID-19 pandemic, elective and routine medical visits and examinations were postponed or discontinued to redirect resources toward providing emergent care for critically ill patients and to prevent the spread of the virus. Healthcare workers were stretched thin, leading to increased turnover rates among full-time and contract workers, which put a strain on the system and reduced the capacity to deliver clinical assistance, negatively impacting the market.
Market Segmentation
By Drug Class
• Tissue Plasminogen Activators (TPA)
• Anticoagulants
• Antiplatelets
• Statins
• Antihypertensives
• Others
By Route of Administration
• Oral
• Parenteral
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In September 2023, Sun Pharmaceutical Industrie's wholly-owned associate unit collaborated with US-based Pharmazz Inc to commercialise a drug utilized to treat cerebral ischemic stroke in India.
• In February 2023, the US Food and Drug Administration (FDA) has allocated a move ahead letter for Pharmazz’s investigational new drug (IND) application to initiate a Phase III clinical trial of Sovateltide (PMZ-1620) in acute cerebral ischaemic stroke patients.
Competitive Landscape
The major global players in the market include Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Amgen Inc., Merck and Co. Inc. and Biogen Inc. among others.
Why Purchase the Report?
• To visualize the global ischemic stroke treatment market segmentation based on drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of ischemic stroke treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global ischemic stroke treatment market report would provide approximately 61 tables, 59 figures and 194 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Route of Administration
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Growing Prevalence
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Availability of Substituents
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. Pipeline Analysis
5.8. Epidemiology
5.9. SWOT Analysis
5.10. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Class
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
7.1.2. Market Attractiveness Index, By Drug Class
7.2. Tissue Plasminogen Activators (TPA)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Anticoagulants
7.4. Antiplatelets
7.5. Statins
7.6. Antihypertensives
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail pharmacies
9.4. Online pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Hoffmann-La Roche*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Pfizer
12.3. Bristol-Myers Squibb, Inc.
12.4. Boehringer Ingelheim GmbH
12.5. Sanofi
12.6. Daiichi Sankyo
12.7. AstraZeneca, Inc.
12.8. Amgen Inc.
12.9. Biogen Inc.
12.10. Merck and Co. Inc.
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Hoffmann-La Roche, 4.	Key Developments, Pfizer, Bristol-Myers Squibb, Inc., Boehringer Ingelheim GmbH, Sanofi, Daiichi Sankyo, AstraZeneca, Inc., Amgen Inc., Biogen Inc., Merck and Co. Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Ischemic Stroke Treatment Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Ischemic Stroke Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Ischemic Stroke Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Ischemic Stroke Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Ischemic Stroke Treatment Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 7 Global Ischemic Stroke Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 9 Global Ischemic Stroke Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Ischemic Stroke Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Ischemic Stroke Treatment Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 14 North America Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 15 North America Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Ischemic Stroke Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 18 South America Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 19 South America Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Ischemic Stroke Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 22 Europe Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 23 Europe Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Ischemic Stroke Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Ischemic Stroke Treatment Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Ischemic Stroke Treatment Market Value, By Drug Class, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Ischemic Stroke Treatment Market Value, By Route of Administration, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Ischemic Stroke Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Hoffmann-La Roche: Overview

Table 33 Hoffmann-La Roche: Product Portfolio

Table 34 Hoffmann-La Roche: Key Developments

Table 35 Pfizer: Overview

Table 36 Pfizer: Product Portfolio

Table 37 Pfizer: Key Developments

Table 38 Bristol-Myers Squibb, Inc.: Overview

Table 39 Bristol-Myers Squibb, Inc.: Product Portfolio

Table 40 Bristol-Myers Squibb, Inc.: Key Developments

Table 41 Boehringer Ingelheim GmbH: Overview

Table 42 Boehringer Ingelheim GmbH: Product Portfolio

Table 43 Boehringer Ingelheim GmbH: Key Developments

Table 44 Sanofi: Overview

Table 45 Sanofi: Product Portfolio

Table 46 Sanofi: Key Developments

Table 47 Daiichi Sankyo: Overview

Table 48 Daiichi Sankyo: Product Portfolio

Table 49 Daiichi Sankyo: Key Developments

Table 50 AstraZeneca, Inc.: Overview

Table 51 AstraZeneca, Inc.: Product Portfolio

Table 52 AstraZeneca, Inc.: Key Developments

Table 53 Amgen Inc.: Overview

Table 54 Amgen Inc.: Product Portfolio

Table 55 Amgen Inc.: Key Developments

Table 56 Biogen Inc.: Overview

Table 57 Biogen Inc.: Product Portfolio

Table 58 Biogen Inc.: Key Developments

Table 59 Merck and Co. Inc.: Overview

Table 60 Merck and Co. Inc.: Product Portfolio

Table 61 Merck and Co. Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 2 Global Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 4 Global Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Ischemic Stroke Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Ischemic Stroke Treatment Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Tissue Plasminogen Activators (TPA) Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 8 Anticoagulants Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 9 Antiplatelets Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 10 Statins Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 11 Antihypertensives Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 12 Others Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 13 Global Ischemic Stroke Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 14 Oral Route of Administration in Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 15 Parenteral Route of Administration in Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 16 Global Ischemic Stroke Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 17 Hospital pharmacies Distribution Channel in Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 18 Retail pharmacies Distribution Channel in Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 19 Online pharmacies Distribution Channel in Global Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 20 Global Ischemic Stroke Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 22 Asia-Pacific Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 23 Europe Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 24 South America Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 25 Middle East and Africa Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 26 North America Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 27 North America Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 28 North America Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 29 North America Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 30 North America Ischemic Stroke Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 31 South America Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 32 South America Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 33 South America Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 34 South America Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 35 South America Ischemic Stroke Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 36 Europe Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 37 Europe Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 Europe Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 Europe Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 Europe Ischemic Stroke Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Asia-Pacific Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 42 Asia-Pacific Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 43 Asia-Pacific Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 44 Asia-Pacific Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 45 Asia-Pacific Ischemic Stroke Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 46 Middle East & Africa Ischemic Stroke Treatment Market Value, 2021-2030 (US$ Million)

Figure 47 Middle East & Africa Ischemic Stroke Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 48 Middle East & Africa Ischemic Stroke Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 49 Middle East & Africa Ischemic Stroke Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 50 Hoffmann-La Roche: Financials

Figure 51 Pfizer: Financials

Figure 52 Bristol-Myers Squibb, Inc.: Financials

Figure 53 Boehringer Ingelheim GmbH: Financials

Figure 54 Sanofi: Financials

Figure 55 Daiichi Sankyo: Financials

Figure 56 AstraZeneca, Inc.: Financials

Figure 57 Amgen Inc.: Financials

Figure 58 Biogen Inc.: Financials

Figure 59 Merck and Co. Inc.: Financials

글로벌 허혈성 뇌졸중 치료 시장 – 2023-2030

Global Ischemic stroke Treatment Market - 2023-2030